Izyan Mohd Idris1*, Rosnani Mohamed1, Nur Jannaim Muhamad1, Fatimah Diana Amin Nordin1, Fazlina Nordin2, Adiratna Mat Ripen1, Julaina Abd Jalil1
1. Inborn Errors of Metabolism & Genetics Unit, Nutrition, Metabolism & Cardiovascular Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Malaysia
2. Department for Tissue Engineering and Regenerative Medicine (DTERM), Universiti Kebangsaan Malaysia (UKM)
*Corresponding author: Izyan Mohd Idris.
ABSTRACT
INTRODUCTION: Mitochondrial membrane potential (MMP) is a key indicator of mitochondrial function, essential for ATP synthesis, calcium regulation, and redox balance. Loss of MMP is a hallmark of mitochondrial dysfunction, commonly observed in metabolic and neurodegenerative diseases.
OBJECTIVE(S): This study aimed to develop, optimise, and validate a high-content image analysis (HCA) assay to quantify MMP in primary human dermal fibroblasts. The assay was subsequently applied to assess mitochondrial function in fibroblasts derived from a patient carrying a pathogenic ND6 mitochondrial DNA mutation.
MATERIALS & METHODS: MMP was assessed using Mitotracker Red CMXRos (MTR), which accumulates in mitochondria in a membrane potential-dependent manner, and Mitotracker Green (MTG), which labels mitochondrial mass independent of MMP. To optimise assay conditions, cells were treated with increasing concentrations (0–100 μM) of carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), a mitochondrial uncoupler that induces MMP depolarisation. High-content images were acquired using the Operetta system and analysed with Harmony software. The optimized assay was then validated by comparing MMP in ND6-mutant and healthy control fibroblasts.
RESULTS: FCCP treatment led to a dose-dependent decrease in MTR intensity, with 10 μM identified as the optimal concentration that reduced MMP without inducing significant cytotoxicity. Multiparametric toxicity analysis confirmed morphological changes and increased mitochondrial mass at higher FCCP doses. The validated assay detected MMP reductions across all tested cell types. ND6-mutant fibroblasts showed a 5–10% reduction in MMP relative to controls, although the difference did not reach statistical significance (p = 0.07). Mitochondrial mass was comparable between all lines.
CONCLUSION: This HCA-based assay provides a robust and reproducible method to assess mitochondrial membrane potential in human fibroblasts. It holds promise as a functional readout of mitochondrial health in disease modelling and screening of mitochondrial dysfunction in patient-derived cells.
KEYWORDS: Mitochondrial Membrane Potential, High-Content Imaging, Fibroblasts, Metabolic Health, ND6 Mutation


